Drug · CHEMBL930
GLUTAMINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. GLUTAMINE. Drugs and targets, record CHEMBL930. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL930
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases42
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 42Source Open Targets
See all 42 diseasesTrials83
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more rests on that reading alone and is shown because the trial's posted result groups or NLM's indexing of its papers name the drug. 9 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01179217 | A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia | Phase 3 | 230 | 2017-08-10 | glutamine | Its name | ClinicalTrials.gov |
| NCT01414244 | Glutamine for the Treatment of Patients With Irritable Bowel Syndrome | Phase 2 | 106 | 2017-08-09 | glutamine | Its name | ClinicalTrials.gov |
| NCT01952847 | Randomized Trial of Glutamine in Patients With Mucositis or Esophagitis | Phase 3 | 77 | 2022-06-15 | glutamine | Its name | ClinicalTrials.gov |
| NCT00125788 | L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia | Phase 2 | 70 | 2021-01-29 | l-glutamine | Its name | ClinicalTrials.gov |
| NCT04560309 | Role of Glutamine as Myocardial Protector in Elective On-Pump CABG Surgery With Low EF | Phase 3 | 60 | 2023-11-13 | glutamine | Its name | ClinicalTrials.gov |
| NCT00365768 | Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors | Phase 2 | 56 | 2016-09-09 | glutamine | Its name | ClinicalTrials.gov |
| NCT01607879 | Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation | Phase 2 | 48 | 2023-09-22 | glutamine | Its name | ClinicalTrials.gov |
| NCT01534663 | Supplementation of Glutamine and Fish Oil Versus Placebo in Patients With Heart Failure | Phase 2/3 | 31 | 2020-12-22 | glutamine | Its name | ClinicalTrials.gov |
| NCT00195013 | Randomized Placebo-Controlled Trial of Glutamine for Breast Cancer Patients With Peripheral Neuropathy | Phase 3 | 30 | 2017-08-18 | glutamine | Its name | ClinicalTrials.gov |
| NCT00131508 | Trial of Oral Glutamine in Patients With Sickle Cell Anemia | Phase 2 | 27 | 2010-05-12 | glutamine | Its name | ClinicalTrials.gov |
1 to 10 of 83
See all 83 trialsComparisons in its trials29
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| L-glutamine vs 100% Maltodextrin: serious adverse events | 118 of 151 | 68 of 78 | 229 | NCT01179217 | Trial comparisons |
| Glutamine vs Placebo: deaths from any cause | 0 of 54 | 0 of 52 | 106 | NCT01414244 | Trial comparisons |
| Glutamine vs Placebo: serious adverse events | 0 of 54 | 0 of 52 | 106 | NCT01414244 | Trial comparisons |
| Investigational Product vs Placebo: deaths from any cause | 1 of 37 | 0 of 33 | 70 | NCT00125788 | Trial comparisons |
| Investigational Product vs Placebo: serious adverse events | 24 of 37 | 21 of 33 | 70 | NCT00125788 | Trial comparisons |
| Glutamine vs Control: deaths from any cause | 0 of 30 | 0 of 30 | 60 | NCT04560309 | Trial comparisons |
| Glutamine vs Control: serious adverse events | 0 of 30 | 0 of 30 | 60 | NCT04560309 | Trial comparisons |
| Arm I: Glutamine vs Arm II: Placebo: Incidence of Vincristine-induced Peripheral Neuropathy | 24 of 24 | 25 of 25 | 49 | NCT00365768 | Trial comparisons |
| Arm I: Glutamine vs Arm II: Placebo: Number of Participants With Progression of Neuropathy | 11 of 24 | 19 of 25 | 49 | NCT00365768 | Trial comparisons |
| Arm I: Glutamine vs Arm II: serious adverse events | 0 of 24 | 0 of 25 | 49 | NCT00365768 | Trial comparisons |
1 to 10 of 29
See all 29 comparisons in its trialsPapers from its trials65
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL930
GET https://conductscience.org/api/drugs/v1/CHEMBL930/diseases?page=2